Cancer Discovery · 2023 · 97 citations · 19 references
MedicineOncologyPharmacologyCancer PharmacologyImmunotherapyTumor ImmunologyCancer ImmunotherapyGenitourinary Cancer PharmacotherapyImmunotherapy For Genitourinary CancersMetastatic Disease TreatmentProstate CancerTargeted TherapyAdvanced Prostate Cancer TherapyCastration-resistant Prostate Cancer TherapyCytokine Mediator ReleaseMetastatic Castration-resistant Prostate CancerProstate Cancer ImmunotherapyProstate-specific Antigen - Targeted TherapyRecist CriteriaTargeted Immunotherapy
Xaluritamig (AMG 509) is a six-transmembrane epithelial antigen of the prostate 1 (STEAP1)-targeted T-cell engager designed to facilitate lysis of STEAP1-expressing cancer cells, such as those in advanced prostate cancer. This first-in-human study reports monotherapy dose exploration for patients with metastatic castration-resistant prostate cancer (mCRPC), primarily taxane pretreated. Ninety-seven patients received ≥1 intravenous dose ranging from 0.001 to 2.0 mg weekly or every 2 weeks. MTD was identified as 1.5 mg i.v. weekly via a 3-step dose. The most common treatment-related adverse events were cytokine release syndrome (CRS; 72%), fatigue (45%), and myalgia (34%). CRS occurred primarily during cycle 1 and improved with premedication and step dosing. Prostate-specific antigen (PSA) and RECIST responses across cohorts were encouraging [49% PSA50; 24% objective response rate (ORR)], with greater frequency at target doses ≥0.75 mg (59% PSA50; 41% ORR). Xaluritamig is a novel immunotherapy for prostate cancer that has shown encouraging results supporting further development. SIGNIFICANCE: Xaluritamig demonstrated encouraging responses (PSA and RECIST) compared with historical established treatments for patients with late-line mCRPC. This study provides proof of concept for T-cell engagers as a potential treatment for prostate cancer, validates STEAP1 as a target, and supports further clinical investigation of xaluritamig in prostate cancer. See related commentary by Hage Chehade et al., p. 20. See related article by Nolan-Stevaux et al., p. 90. This article is featured in Selected Articles from This Issue, p. 5.
19
Rebecca L. Siegel, Kimberly D. Miller, Nikita Sandeep Wagle et al. · CA A Cancer Journal for Clinicians · 2023 · 16.7K citations · Full text
Current concepts in the diagnosis and management of cytokine release syndrome
Daniel W. Lee, Rebecca Gardner, David Porter et al. · Blood · 2014 · 2.8K citations
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop Kantarjian, Anthony S. Stein, Nicola Gökbuget et al. · New England Journal of Medicine · 2017 · 2.1K citations · Full text
Medicine, Hematology, Oncology +16